Stephen Bardin Biography and Net Worth

CFO of CalciMedica

Mr. Bardin has more than 10 years of life sciences experience across finance, operations, and corporate development. Prior to CalciMedica, he served as Chief Financial Officer of atai Life Sciences and held finance leadership roles at BridgeBio Pharma and Myovant Sciences.

What is Stephen Bardin's net worth?: The estimated net worth of Stephen Bardin is at least $894.00 as of June 26th, 2025. Mr. Bardin owns 600 shares of CalciMedica stock worth more than $894 as of October 7th. This net worth estimate does not reflect any other assets that Mr. Bardin may own. Learn More about Stephen Bardin's net worth.
How do I contact Stephen Bardin?: The corporate mailing address for Mr. Bardin and other CalciMedica executives is 505 Coast Boulevard South, Suite 307, LA Jolla, CA, 92037. CalciMedica can also be reached via phone at 858-952-5500 and via email at [email protected]. Learn More on Stephen Bardin's contact information.
Has Stephen Bardin been buying or selling shares of CalciMedica?: Stephen Bardin has not been actively trading shares of CalciMedica over the course of the past ninety days. Most recently, on Thursday, June 26th, Stephen Bardin bought 400 shares of CalciMedica stock. The stock was acquired at an average cost of $7.50 per share, with a total value of $3,000.00. Following the completion of the transaction, the chief financial officer now directly owns 600 shares of the company's stock, valued at $4,500. Learn More on Stephen Bardin's trading history.
Who are CalciMedica's active insiders?: CalciMedica's insider roster includes Stephen Bardin (CFO), A. Leheny (CEO), Eric Roberts (Insider), and Kenneth Stauderman (Chief Scientific Officer). Learn More on CalciMedica's active insiders.
Are insiders buying or selling shares of CalciMedica?: In the last twelve months, CalciMedica insiders bought shares 1 times. They purchased a total of 49,794 shares worth more than $199,176.00. The most recent insider tranaction occured on June, 25th when Director Fred A Middleton bought 49,794 shares worth more than $199,176.00. Insiders at CalciMedica own 28.3% of the company. Learn More about insider trades at CalciMedica.
Information on this page was last updated on 6/25/2026.

Stephen Bardin Insider Trading History at CalciMedica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/26/2025	Buy	400	$7.50	$3,000.00	600

Stephen Bardin Buying and Selling Activity at CalciMedica

CalciMedica Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Today's Range

Now: $1.47

$1.49

50 Day Range

MA: $2.55

$1.49

$5.00

2 Week Range

Now: $1.47

$1.42

$36.00

Volume

315 shs

Average Volume

187,891 shs

Market Capitalization

$10.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76